Gregory B. Brown - 10 Jun 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: Director
Issuer ticker: AQST
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 11:42:23 UTC
Prior SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas Zalewski, as Attorney-In-Fact

Key filing fact

Gregory B. Brown filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 12 Jun 2026.

Key facts

This page summarizes Gregory B. Brown's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 11:42.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001373585 Primary reporting owner

BROWN GREGORY B

Relationship: Director
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Thomas Zalewski, as Attorney-In-Fact
Signature date: 11 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 75,085
Date: 10 Jun 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Stock Option (Right to Purchase)

Award

Transaction value
Shares: +50,500
Change %
Price: $0.000000^*
Shares after: 50,500
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,500
Exercise price: $3.99
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date.